Gates George A, Verrall Aimee M
Department of Otolaryngology-Head and Neck Surgery and the Virginia Merrill Bloedel Hearing Research Center, University of Washington, Seattle 98195-7923, USA.
Arch Otolaryngol Head Neck Surg. 2005 Oct;131(10):863-7. doi: 10.1001/archotol.131.10.863.
To validate a disease-specific, health-related quality-of-life instrument for people with active, unilateral, cochleovestibular Ménière's disease (MD).
Prospective, blinded, randomized cohort study using a 16-item instrument, the Ménière's Disease Patient-Oriented Symptom-Severity Index (MDPOSI), version 2.
Four clinical sites, including 3 university hospitals and 1 private practice.
Sixty-one adult participants in a clinical trial of a new treatment modality (the Meniett device) at 4 medical centers.
The MDPOSI was administered at baseline and at 2 and 4 months after the use of the Meniett device or the placebo.
Each item, domain, and overall MDPOSI score was compared with self-reported cumulative frequency of definitive attacks of vertigo at baseline and 2 and 4 months later.
The MDPOSI global score, domain scores, and 13 of 16 items were significantly associated with the frequency of vertigo (gold standard) as noted on the daily symptom report card.
The MDPOSI is a valid and reliable instrument to evaluate the impact of MD on patients' disease-related quality of life, and it is responsive to change in the status of the disorder. The MDPOSI is suitable for use in clinical practice and clinical research in people with MD.
验证一种针对单侧活动性耳蜗前庭梅尼埃病（MD）患者的特定疾病、与健康相关的生活质量评估工具。
前瞻性、盲法、随机队列研究，使用包含16个条目的梅尼埃病患者导向症状严重程度指数（MDPOSI）第2版工具。
四个临床地点，包括3所大学医院和1所私人诊所。
4个医疗中心一项新治疗方式（美尼埃氏治疗仪）临床试验中的61名成年参与者。
在基线时以及使用美尼埃氏治疗仪或安慰剂后2个月和4个月时进行MDPOSI评估。
将每个条目、领域及MDPOSI总分与基线时以及2个月和4个月后自我报告的明确眩晕发作累积频率进行比较。
MDPOSI总体评分、领域评分以及16个条目中的13个与每日症状报告卡上记录的眩晕频率（金标准）显著相关。
MDPOSI是一种有效且可靠的工具，可用于评估MD对患者疾病相关生活质量的影响，并且对疾病状态的变化有反应。MDPOSI适用于MD患者的临床实践和临床研究。
